

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031181 A1

(51) International Patent Classification⁷: C07D 409/12,
413/14, 417/14, 409/14, A61K 31/55, A61P 25/00

GlaxoSmithKline, New Frontiers Science Park South,
Third Avenue, Harlow, Essex CM19 5AW (GB).

(21) International Application Number:
PCT/EP2003/011174

(74) Agent: MCKINNEL, Denise; GlaxoSmithKline, CIP
(CN925.1), 980 Great West Road, Brentford, Middlesex
TW8 9GS (GB).

(22) International Filing Date: 6 October 2003 (06.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0223226.2 7 October 2002 (07.10.2002) GB
0223236.1 7 October 2002 (07.10.2002) GB
0314627.1 23 June 2003 (23.06.2003) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): FORBES, Ian, Thomson [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). GRIBBLE, Andrew, Derrick [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). LIGHT-FOOT, Andrew, P. [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PAYNE, Andrew, H. [GB/GB];

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS




(I)

(57) Abstract: The invention provides compounds of formula (I) wherein A and B represent the groups $-(CH_2)_m-$ and $-(CH_2)_n-$ respectively; R^1 represents C_{1-6} alkyl; R^2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C_{1-6} alkyl, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_pC_{3-6}$ cycloalkyl, $-(CH_2)_pOC_{3-6}cy-$

cloalkyl, $-COC_{1-6}alkyl$, $-SO_2C_{1-6}alkyl$, $-SOC_{1-6}alkyl$, $-SC_{1-6}alkyl$, $-CO_2C_{1-6}alkyl$, $-CO_2NR^4R^5$, $-SO_2NR^4R^5$, $-(CH_2)_pNR^4R^5$, $-(CH_2)_pNR^4COR^5$, an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted heterocyclyl group; R^3 represents hydrogen or C_{1-6} alkyl; Ar^1 represents an optionally substituted heteroaryl group; Ar^2 represents an optionally substituted phenyl or an optionally substituted heteroaryl group; Y represents a bond, $-O-$, $-C_{1-6}alkyl-$, $-CR^6R^7X-$, $-XCR^6R^7-$, $-NR^8CO-$ or $-CONR^8-$; X represents oxygen, sulfur, $-SO-$ or $-SO_2-$; R^4 and R^5 each independently represent hydrogen or C_{1-6} alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R^6 and R^7 each independently represent hydrogen, C_{1-6} alkyl or fluoro; R^8 represents hydrogen or C_{1-6} alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt, solvate or pharmaceutically acceptable derivative thereof. The compounds are useful in therapy, in particular as antipsychotic agents.

ABSTRACT OF THE DISCLOSURE

The invention provides compounds of formula (I):



wherein

A and B represent the groups $-(CH_2)_m-$ and $-(CH_2)_n-$ respectively;

R^1 represents hydrogen or C_{1-6} alkyl;

R^2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C_{1-6} alkyl, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} fluoroalkoxy, $-(CH_2)_pC_{3-6}$ cycloalkyl, $-(CH_2)_pOC_{3-6}$ cycloalkyl, $-COC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, $-SOC_{1-6}$ alkyl, $-SC_{1-6}$ alkyl, $-CO_2C_{1-6}$ alkyl, $-CO_2NR^5R^6$, $-SO_2NR^5R^6$, $-(CH_2)_pNR^5R^6$, $-(CH_2)_pNR^5COR^6$, optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring;

R^3 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C_{1-6} alkyl, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} fluoroalkoxy, $-(CH_2)_pC_{3-6}$ cycloalkyl, $-(CH_2)_pOC_{3-6}$ cycloalkyl, $-COC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, $-SOC_{1-6}$ alkyl, $-SC_{1-6}$ alkyl, $-CO_2C_{1-6}$ alkyl, $-CO_2NR^7R^8$, $-SO_2NR^7R^8$, $-(CH_2)_pNR^7R^8$ or $-(CH_2)_pNR^7COR^8$;

R^4 represents hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, $-OSO_2CF_3$, $-(CH_2)_pC_{3-6}$ cycloalkyl, $-(CH_2)_qOC_{1-6}$ alkyl or $-(CH_2)_pOC_{3-6}$ cycloalkyl;

R^5 and R^6 each independently represent hydrogen, C_{1-6} alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;

R^7 and R^8 each independently represent hydrogen or C_{1-6} alkyl;

m and n independently represent an integer selected from 1 and 2;

p independently represents an integer selected from 0, 1, 2 and 3;

q independently represents an integer selected from 1, 2 and 3;

or a pharmaceutically acceptable salt or solvate thereof,

with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.

The compounds are useful in therapy, in particular as antipsychotic agents